Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric inebilizumab study in neuromyelitis optica spectrum disorder
NL-OMON60525Phase 2Not yet recruiting
- Sponsor
- Horizon Therapeutics
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Horizon Therapeutics. Primary endpoints: Pharmacokinetic parameters, Pharmacodynamic B-cell depletion and 1 more. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NL-OMON60525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60525.